Primary cutaneous B-cell lymphoma

Report of a case and review of the English-language literature

Gary R. Kantor, M.D.
Richard E. Ranchoff, M.D.
Raymond R. Tubbs, D.O.
Willard D. Steck, M.D.

Dermatology Feature
Kenneth J. Tomecki, M.D.
Section Editor

B-cell lymphomas may involve the skin late in the course of the disease, but only infrequently have primary presentation in the skin. The cutaneous lesions are red-to-violaceous nodules, most often located on the head and neck. Most patients have been treated with radiation alone or combined with surgical excision of the tumors or systemic chemotherapy. In general, patient survival has been poor. The authors report a case of B-cell lymphoma initially confined to the skin and review the clinical characteristics of these lymphomas as reported in the English-language literature.

Index terms: Dermatology features • Lymphoma

Clev Clin Q 52:87–93, Spring 1985

Malignant lymphoma of the skin may be of T-cell or B-cell origin.1 Cutaneous T-cell lymphomas (CTCL) are more common and include mycosis fungoides and its leukemic variant, Sezary syndrome. These T-cell lymphomas are epidermotropic and present first in the skin and only later involve lymphatic and visceral tissue. CTCL is immunologically defined by monoclonal antibodies to T4, T8, and T1 differentiation antigens. Cutaneous B-cell lymphomas (CBCL) are less commonly reported,1-5 although a recent series found a 32% frequency of malignant lymphoma of the skin to be of B-cell origin.6 Primary presentation of CBCL in the skin is less common than CTCL. CBCL is defined immunologically by polyclonal antibodies to immunoglobulin heavy and light chains and monoclonal antibodies to B1 antigen.

We report a case of CBCL with initial presentation only in the skin.

Case report

A 66-year-old white man presented to the Cleveland Clinic’s Department of Dermatology with a six-month history of pruritic and slightly tender nodules on the scalp, abdomen, and extremities. Previous treatment with topical and systemic corticosteroids had been unsuccessful. The patient reported no fevers, night sweats, or weight loss, and the medical history was otherwise noncontributory.

On physical examination, there were numerous violaceous and hyperpigmented, indurated nodules and plaques on the head, chest, back, and extremities (Fig. 1). Shotty left axillary adenopathy was present, but otherwise the remainder of the physical examination was normal.

Results of laboratory studies, including a complete blood cell count, SMA-18, Westergren sedimentation rate, rapid plasma reagin, antinuclear antibody, serum protein electrophoresis, acid phosphatase, and buffy coat for Sezary cells, were normal or negative with the exception of random glucose (260 mg/dL [normal, 70–110 mg/dL]). Other results were: triglycerides, 455 mg/dL (normal, 35–135 mg/dL); lipoprotein electrophoresis, consistent with a type IV pattern; circulating T cells, 82.4% (normal, 75.2 ± 5.3%); and circulating B cells, 14.8% (normal, 21.8 ± 6.1%). Delayed hypersensitivity reaction to purified protein derivative was negative, whereas reactions to Trichophyton and
Monilia were positive. Results of radiographic studies, including chest roentgenography, upper and lower gastrointestinal series, bone scan, lymphangiography, intravenous pyelography, and computed tomography of the abdomen and pelvis, were normal. Bone marrow biopsy findings revealed mild hypercellularity with erythroid predominance.

Results of a skin biopsy of a nodule on the extremity showed malignant lymphoma (Figs. 2 and 3) classified as intermediate grade, large noncleaved cell by the International Working Formulation (Rappaport equivalent, histiocytic lymphoma; Luke’s-Collins equivalent, large noncleaved follicular center cell lymphoma). Immunohistology (Table 1) documented an immunophenotype consistent with a monoclonal B-cell proliferation (γ-α-δ+ε-κ-λ+α+β+λ5-12 +LN1+LN2+T11-T3-). Direct immunofluorescence of skin biopsy specimen was negative for extra-cellular immune complexes.

A diagnosis of primary CBCL was made because there was no clinical evidence of extracutaneous involvement. Treatment with systemic chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was given. The nodules resolved, but recurred three months later; the patient was re-treated with CHOP-bleomycin regimen. Six months after initial treatment, high fevers developed and lymphomatous involvement of the bone marrow was found. A partial remission of the lymphoma occurred after a two-month hospitalization and treatment with cytosine arabinoside, cisplatin, and etoposide.

Discussion

Extranodal non-Hodgkin’s lymphoma may arise in the skin, orbit, salivary glands, gonad, thyroid, breast, lung, and gastrointestinal tract. Clinical course and survival rates vary widely from each site of origin. One large series of 1,467 patients found five-year relative survival rates of approximately 60% for lymphomas arising in the skin, salivary gland, connective tissue, and lung, but less than half of that for small intestine, adenoid, and testis.

From 1972 to 1983, there have been several reports of cutaneous non-Hodgkin’s lymphoma in the English-language literature (Table 2). A total of 196 patients was described (mean age, 56.2 years; slight male predominance). Most nodules were red-to-purple or violaceous and most
were solitary (from 16% in one series to 84% in another). The head and neck were the most common sites of skin nodules in six of the eight series. Most patients were treated with radiation therapy alone or combined with surgical excision of the tumors or systemic chemotherapy. Patient survival was generally poor.

Immunologic analysis of our patient's lymphoma was compatible with B-cell origin. We found four other reports in the English-language literature of patients with CBCL. Knowles et al² described 1 patient with CBCL which presented three years after nodal lymphoma was diagnosed. Willemze et al³ described 3 patients with CBCL. Lymphatic or visceral disease subsequently developed in these patients and they died. In the largest series, Wood et al⁴ described 10 patients with CBCL, 5 of whom had primary CBCL. Two of the 5 patients died with visceral disease. Goldberg et al⁵ reported a case of lymphoma cutis of B-cell origin that also involved the lymph nodes and spleen. Their patient was

Fig. 2. A. Photomicrograph shows dense collection of atypical mononuclear cells in the dermis which spare the epidermis (hematoxylin-eosin, X160).

B. On higher magnification, large noncleaved cells with small nucleoli, some in apposition to the nuclear membrane, are the predominant cell type (hematoxylin-eosin, X400).
treated with systemic chemotherapy and the disease regressed. Other authors have not classified cutaneous non-Hodgkin’s lymphoma into immunologic types. It appears from the cited reports that primary CBCL is uncommon.

A recently published series of 736 patients from Germany and Austria with “cutaneous lymphomas primarily showing skin manifestations” showed that 32% were of B-cell type. The authors differentiated CBCL from CTCL based on clinical, morphologic, and functional criteria. The clinical characteristics of CBCL and CTCL are well-known and helpful discriminating criteria. A morphologic diagnosis of CBCL, however, is often difficult and not as straightforward as these authors imply. In fact, prediction of immunologic phenotype using light microscopy alone is successful in approximately 61%–81% of cases of histiocytic lymphoma involving lymph nodes. Epidermotropism may rarely be found

Fig. 3. A. Photomicrograph shows lymphoma cells which express LN2, a marker for B cells using the avidin-biotinylated peroxidase technique.
B. A negative control section shows no immunostaining when nonimmune mouse plasmacytoma supernatant is substituted for primary mouse monoclonal antibody. (× 240)
Table 1. Specificity of antibodies used in this study

<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Source</th>
<th>Primary Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>T₁₁</td>
<td>Coulter</td>
<td>T cells (sheep erythrocyte receptor positive)</td>
</tr>
<tr>
<td>T₃</td>
<td>Coulter</td>
<td>T cells</td>
</tr>
<tr>
<td>B₁</td>
<td>Coulter</td>
<td>B cells</td>
</tr>
<tr>
<td>J₅</td>
<td>Coulter</td>
<td>Early B cells</td>
</tr>
<tr>
<td>I₂</td>
<td>Coulter</td>
<td>Ia-like antigens (B cells, some activated T cells, macrophages)</td>
</tr>
<tr>
<td>LN₁</td>
<td>Techniclone</td>
<td>Follicular center B cells, macrophages</td>
</tr>
<tr>
<td>LN₂</td>
<td>Techniclone</td>
<td>B cells, dendritic reticulum cells</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Polyclonal Antibody</th>
<th>Primary Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO goat antihuman IgG (Fc specific)</td>
<td>( \gamma ) (IgG) heavy chains</td>
</tr>
<tr>
<td>PO goat antihuman IgA (Fc specific)</td>
<td>( \alpha ) (IgA) heavy chains</td>
</tr>
<tr>
<td>PO goat antihuman IgM (Fc specific)</td>
<td>( \mu ) (IgM) heavy chains</td>
</tr>
<tr>
<td>PO goat antihuman IgD (Fc specific)</td>
<td>( \delta ) (IgD) heavy chains</td>
</tr>
<tr>
<td>PO goat antihuman K</td>
<td>( \lambda ) light chains</td>
</tr>
<tr>
<td>PO goat antihuman ( \lambda )</td>
<td>( \lambda ) light chains</td>
</tr>
</tbody>
</table>

PO = Peroxidase enzyme conjugated to antibody.

in B-cell neoplasms, and some of the CTCLs may be nonepidermotropic. Therefore, diagnosis of CBCL by morphology is not error-free. Surface markers for B cells used in the German and Austrian series include HLA-DR/Ia, Ig, and C₃. It is well known, however, that macrophages, histiocytes, and Langerhan's cells are also identified by the HLA-DR/Ia antigens. Lastly, the authors used only monoclonal intracytoplasmic immunoglobulins in some cases to diagnose CBCL.

We used both monoclonal and polyclonal antibodies to diagnose CBCL in our patient (Table 1). Monoclonal antibodies are more specific than surface markers for detecting cell surface antigens. In addition, cytochemistry or immunohistochemistry is necessary to make a reliable discrimination between small T and B lymphocytes as compared to light microscopy. Therefore, we are confident of the diagnosis of CBCL in our patient.

The discrepancy in the prevalence of primary CBCL as reported by Burg et al compared to previous reports is disconcerting. Burg et al made the diagnosis of primary CBCL using "routine and special staging procedures." These procedures, however, are not defined; therefore, it is impossible to compare their data with those of previous reports to affect a significant change in prognosis of patients with these tumors. Clinical evaluation to uncover lymphatic or visceral disease has been described by the Committee on Hodgkin's Disease Staging Procedures (Ann Arbor System). Our patient may exemplify the limitations of present staging and diagnostic procedures. Although it is conceivable that extracutaneous lymphoma was present in our patient at initial evaluation but was undetected, it is doubtful based on our patient's initial good health and lack of symptoms.

**Summary**

Primary CBCL is an underreported tumor. It presents as solitary or multiple red-to-violaceous nodules usually on the head and neck. The patient prognosis is generally poor with standard treatment regimens, which are usually radiation therapy alone or combined with surgical excision.
<table>
<thead>
<tr>
<th>No.</th>
<th>Males</th>
<th>Females</th>
<th>NDF</th>
<th>Red-</th>
<th>Blue-</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>9</td>
<td>10</td>
<td>9</td>
<td>3</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>100</td>
<td>6</td>
<td>5</td>
<td>11</td>
<td>14</td>
<td>33</td>
<td>41</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>16</td>
<td>28</td>
<td>32</td>
<td>65</td>
<td>91</td>
</tr>
<tr>
<td>44</td>
<td>6</td>
<td>0</td>
<td>57</td>
<td>38</td>
<td>75</td>
<td>136</td>
</tr>
</tbody>
</table>

TABLE 2. Clinical characteristics of various non-Hodgkin’s lymphomas

<table>
<thead>
<tr>
<th>No.</th>
<th>Males</th>
<th>Females</th>
<th>NDF</th>
<th>Red-</th>
<th>Blue-</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td>18</td>
<td>14</td>
<td>14</td>
<td>64</td>
<td>6</td>
<td>64</td>
</tr>
</tbody>
</table>

Note: M = male, F = female, and NDF = not done.
or systemic chemotherapy. The skin is a clinically apparent organ of involvement in non-Hodgkin’s lymphoma, whereas other extranodal organs, unless symptomatic, are less so. With this in mind, it is hoped that clinicians will recognize and diagnose CBCL with greater frequency early in the course of the disease, and that with early treatment, the prognosis may be improved.

Willard D. Steck, M.D.
Department of Dermatology
The Cleveland Clinic Foundation
9500 Euclid Ave.
Cleveland OH 44106

References